Reduced trabecular meshwork fibrosis
Lower fibronectin and α-SMA staining in the trabecular meshwork.
Therapeutic program / Glaucoma
Gene therapyA new gene therapy
approach to glaucoma.
Local decorin expression targets trabecular meshwork fibrosis and the tissue biology associated with elevated intraocular pressure.
Scientific evidence
Demonstrated biological activity.
Published TGFβ2-driven mouse model · intracameral AAV-IKV–Decorin with Nuc1 [1]
Lower intraocular pressure
Pressure reduction sustained through the final measurement.
Ganglion-cell preservation
Greater preservation of BRN3a-positive retinal ganglion cells in treated eyes.
Therapeutic approach
Targeting tissue biology, not pressure alone.
AAV-IKV–Decorin connects local gene delivery with antifibrotic activity, pressure reduction and neuronal preservation in the same experimental model. This provides a distinct therapeutic approach centered on the tissue changes associated with ocular hypertension.
- Therapeutic candidate
- AAV-IKV–Decorin
- Delivery route
- Intracameral
- Tissue focus
- Trabecular meshwork / anterior segment
Supporting sources
[1] Rao and colleagues. Scientific Reports. 2025;15:8051. DOI: 10.1038/s41598-025-92273-5. ↗
Strategic partnerships
Start with the science.
Technology collaborations, strategic partnerships and investment discussions.